Toluna and Harris Interactive Deliver Weekly Polling for 2022 French Elections
Toluna, the leading consumer insights provider and parent company of Harris Interactive and KuRunData, today announced a joint initiative with Harris Interactive in service of the French Presidential and Legislative elections.
The companies are conducting weekly polling to measure French citizens on their preferred candidates, voting intention, and out-of-polling-station results. Harris Interactive has historically led this polling effort. However, this year, Harris Interactive is officially partnering with its sister company, Toluna, to cover the events. This year’s efforts include over 50 pre-election surveys with over 100,000 people interviewed, as well as 5,000 interviews on election day.
Harris Interactive and Toluna will also partner with leading French TV channel and radio station, M6 and RTL, throughout their coverage of the French elections. Harris Interactive and Toluna experts will first provide estimates of their weekly polling for the first and second rounds of the Presidential election, held Sunday, April 10, 2022, and Sunday, April 24, 2022.
The coverage will be live on M6 and RTL and will also be shared on Toluna and Harris Interactive social media networks from 12:00 PM CEST each election day and continuing throughout the day. The timeline will be as follows:
- 12:00 PM: Initial analysis of voter turnout
- 5:00 PM: Estimates of voter turnout
- 8:00 PM: Initial estimate of Presidential election results
- 8:30 PM onwards: Exclusive insights from “Voting Day” survey fielded by Harris Interactive and Toluna to understand voter motivations and abstentions
- Later in the evening: Refined results in real time
Following the Presidential election, Harris Interactive and Toluna will again work with M6 and RTL to deliver weekly polling for the French Legislative elections on June 12, 2022 and June 19, 2022, providing exclusive analysis and estimations of the French National Assembly’s composition.
The coverage will again feature live on M6 and RTL, available online throughout the evening, as well as on multiple social media channels, including:
- Harris Interactive: harris-interactive.fr / @HarrisInt_FR
- Toluna: tolunacorporate.com / @TolunaCorporate
- M6: groupem6.fr/ @M6, @M6Info, @M6Pro
- RTL: rtl.fr / @RTLFrance
Toluna CEO Frederic-Charles Petit, said: “We are thrilled to bring Toluna and Harris Interactive together to deliver our on-demand, real-time insights as part of this critical initiative in France’s political calendar. This is a great honor, and we look forward to delivering the accurate data the public desires.”
“Citizens today are bombarded with massive amounts of information during the election cycle, and it is essential that they have access to quality data as they evaluate candidates and results. For more than 20 years, Harris Interactive has been proud to deliver some of the most accurate measures of French election results, and we look forward to continuing this tradition in partnership with Toluna,” commented Jean-Daniel Lévy, Senior Vice President of Harris Interactive France and Director of Politics and Opinion Department.
About Toluna
Toluna delivers real-time consumer insights at the speed of the on-demand economy. Harris Interactive simplifies complex decisions with critical consumer intelligence. By fusing Harris’s sector expertise and award-winning research with Toluna’s innovative tools and technology, we strive to push market research toward a better tomorrow.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005266/en/
Contact information
Media Contact
Articulate Communications for Toluna
Audra Tiner
toluna@articulatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom